72

Exendin-4

72 Publications Verification

Cat. No.: HY-13443

CAS No.: 141758-74-9

Purity: 99.95%

Synonyms: Exenatide

Target:

GLP Receptor Apoptosis

Research Areas:

Cardiovascular Disease Metabolic Disease

Exendin‑4 (Exenatide) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin‑4 mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin‑4 inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin‑4 reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin‑4 can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

72

Exendin-4 acetate

72 Publications Verification

Cat. No.: HY-13443A

CAS No.: 914454-01-6

Purity: 99.91%

Synonyms: Exenatide acetate

Target:

GLP Receptor Apoptosis

Research Areas:

Cardiovascular Disease Metabolic Disease

Exendin-4 acetate (Exenatide acetate) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin-4 acetate mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin-4 acetate inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin-4 acetate reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin-4 acetate can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

59

Raleukin

59 Cited Publications

Cat. No.: HY-108841

CAS No.: 143090-92-0

Purity: 99.40%

Synonyms: Kineret; Anakinra

Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

53

Semaglutide

53 Cited Publications

Cat. No.: HY-114118

CAS No.: 910463-68-2

Purity: 99.84%

Target:

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:

Neurological Disease Metabolic Disease Cancer

Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

53

Semaglutide acetate

53 Cited Publications

Cat. No.: HY-114118B

CAS No.: 1997361-85-9

Purity: 99.92%

Target:

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:

Neurological Disease Metabolic Disease Cancer

Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

53

Semaglutide TFA

53 Cited Publications

Cat. No.: HY-114118A

Purity: 99.92%

Target:

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:

Neurological Disease Metabolic Disease Cancer

Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

43

GSK-923295

43 Cited Publications

Cat. No.: HY-10299

CAS No.: 1088965-37-0

Purity: 99.48%

Target:

Kinesin Apoptosis

Research Areas:

Cancer

GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with K_i of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.

Compare

loading...